B-type natriuretic peptide efficacy compared to fragmented QRS for diastolic dysfunction screening in patients with type 2 diabetes

Table 2 Multivariate model analysis on the diastolic dysfunction diagnosis in non-overweight participants

Factors	OR	95%CI	P value
Model 1; AIC: 181.33
Age, 10-year increments	1.59	1.04-2.57	0.044
Sex, male/female	0.52	0.23-1.19	0.118
CAD	0.84	0.33-2.06	0.715
sBP, every 10 mmHg	1.18	0.96-1.47	0.122
HR, every 10/minute	0.98	0.71-1.34	0.881
BNP, per SD	1.69	1.10-2.81	0.028
Model 2; AIC: 176.14
Age, 10-year increments	1.75	1.14-2.84	0.028
Sex, male/female	0.38	0.16-090	0.055
CAD	0.88	0.33-2.21	0.794
sBP, every 10 mmHg	1.22	0.99-1.53	0.073
HR, every 10/minute	0.89	0.65-1.22	0.478
fQRS	3.76	1.71-8.72	0.001
Model 3; AIC: 171.06
Age, 10-year increments	1.59	1.02-2.60	0.047
Sex, male/female	0.40	0.16-0.96	0.040
CAD	0.66	0.24-1.72	0.410
sBP, every 10 mmHg	1.23	0.99-1.54	0.067
HR, every 10/minute	0.96	0.69-1.31	0.786
BNP, per SD	1.89	1.16-3.39	0.023
fQRS	4.17	1.86-9.88	< 0.001

OR: Odds ratio; CI: Confidence interval; AIC: Akaike’s information criterion; BNP: Brain natriuretic peptide; CAD: Coronary artery disease; fQRS: Fragmented QRS; HR: Heart rate; sBP: Systolic blood pressure.